Business Description
Exicure Inc
NAICS : 325411
SIC : 2834
ISIN : US30205M2008
Description
Exicure Inc is a biotechnology company that develops nucleic acid therapies targeting ribonucleic acid against validated targets for neurological disorders and hair loss. It operates in a single segment, which is the discovery, research, and development of treatments based on its SNA (Spherical Nucleic Acid) technology.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.06 | |||||
| Equity-to-Asset | 0.15 | |||||
| Debt-to-Equity | 3.97 | |||||
| Debt-to-EBITDA | -1.93 | |||||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -23.16 | |||||
| Beneish M-Score | 55.8 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 37.1 | |||||
| 3-Year EPS without NRI Growth Rate | 40.7 | |||||
| 3-Year FCF Growth Rate | 55.4 | |||||
| 3-Year Book Growth Rate | -74.5 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 9-Day RSI | 39.77 | |||||
| 14-Day RSI | 43.9 | |||||
| 6-1 Month Momentum % | -1.33 | |||||
| 12-1 Month Momentum % | -41.73 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.71 | |||||
| Quick Ratio | 0.71 | |||||
| Cash Ratio | 0.09 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -43.6 | |||||
| Shareholder Yield % | 0.81 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -1000.6 | |||||
| Net Margin % | -801.4 | |||||
| FCF Margin % | -576.09 | |||||
| ROE % | -155.38 | |||||
| ROA % | -35.42 | |||||
| ROIC % | -50.58 | |||||
| ROC (Joel Greenblatt) % | -62.64 | |||||
| ROCE % | -47.38 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 59.45 | |||||
| PB Ratio | 24.16 | |||||
| Price-to-Tangible-Book | 24.67 | |||||
| EV-to-EBIT | -16.34 | |||||
| EV-to-EBITDA | -20.5 | |||||
| EV-to-Revenue | 130.34 | |||||
| EV-to-FCF | -22.62 | |||||
| Earnings Yield (Greenblatt) % | -6.12 | |||||
| FCF Yield % | -5.52 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Exicure Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.46 | ||
| EPS (TTM) (€) | -1.904 | ||
| Beta | 0.09 | ||
| Volatility % | 86.57 | ||
| 14-Day RSI | 43.9 | ||
| 14-Day ATR (€) | 0.000464 | ||
| 20-Day SMA (€) | 1.48 | ||
| 12-1 Month Momentum % | -41.73 | ||
| 52-Week Range (€) | 1.3 - 4.225 | ||
| Shares Outstanding (Mil) | 3.04 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Exicure Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Exicure Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Exicure Inc Frequently Asked Questions
What is Exicure Inc(FRA:2H0)'s stock price today?
The current price of FRA:2H0 is €1.48. The 52 week high of FRA:2H0 is €4.22 and 52 week low is €1.30.
When is next earnings date of Exicure Inc(FRA:2H0)?
The next earnings date of Exicure Inc(FRA:2H0) is 2025-02-14 Est..
Does Exicure Inc(FRA:2H0) pay dividends? If so, how much?
Exicure Inc(FRA:2H0) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers